This Medudy course is a video tutorial for physicians on the topic of "Quality of care for locally advanced and metastatic urothelial carcinoma in Germany."
Prof. Dr. Carsten Ohlmann, Chief Physician of the Department of Urology at Johanniter-Kliniken Bonn, presents real treatment data and recommendations for guideline-based care.
The course highlights the therapeutic challenge of locally advanced and metastatic urothelial carcinoma, where the quality of systemic treatment is paramount. The results of a national quality assurance initiative from 2022 and 2023, launched by national working groups, will be presented. The retrospective analysis focuses on first-line treatment decisions, the use of avelumab maintenance therapy, and the application of the Galsky criteria to determine platinum suitability. The aim is to close the data gap on guideline-compliant care in Germany and to identify potential for improvement based on real-world treatment data.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
The course was developed with the kind support of Merck.
At the end of this training you will know:
- The therapeutic challenge of locally advanced and metastatic urothelial carcinoma and the central role of systemic therapy.
- the treatment standards relevant at the time of data collection (late 2022 to early 2023) (platinum-based chemotherapy, immune checkpoint inhibitors) and their use, as well as the role of avelumab maintenance therapy.
- The criteria for determining platinum eligibility (Galsky criteria) in patients with advanced urothelial carcinoma.
- the results of a national quality assurance initiative on the reality of healthcare provision and the potential for improvement in Germany derived from these results.
